Aluminium hydroxide stabilised MnFe2O4 and Fe3O4 nanoparticles as dual-modality contrasts agent for MRI and PET imaging

Cui, Xianjin; Belo, Salome; Krüger, Dirk; Yan, Yong; Rosales, Rafael T. M. de; Jauregui-Osoro, Maite; Ye, Haitao; Su, Shi; Máthé, Domokos; Kovács, Noémi; Horváth, Ildikó; Semjeni, Mariann; Sunassee, Kavitha; Szigeti, Krisztián; Green, Mark; Blower, Philip J.

doi:10.1016/j.biomaterials.2014.04.004

Cited by 78 publications

(56 citation statements)

References 26 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Small size, controllable surface potential, superior colloidal stability and fine transverse relaxivity were the properties of this NS as a theranostic probe. 95 …”

Section: Radiolabeled Mnpsmentioning

confidence: 99%

Radiolabeled theranostics: magnetic and gold nanoparticles

et al. 2016

View full text Add to dashboard Cite

Introduction: Growing advances in nanotechnology have facilitated the applications of newly emerged nanomaterials in the field of biomedical/pharmaceutical sciences. Following this trend, the multifunctional nanoparticles (NPs) play a significant role in development of advanced drug delivery systems (DDSs) such as diapeutics/theranostics used for simultaneous diagnosis and therapy. Multifunctional radiolabeled NPs with capability of detecting, visualizing and destroying diseased cells with least side effects have been considered as an emerging filed in presentation of the best choice in solving the therapeutic problems. Functionalized magnetic and gold NPs (MNPs and GNPs, respectively) have produced the potential of nanoparticles as sensitive multifunctional probes for molecular imaging, photothermal therapy and drug delivery and targeting. Methods: In this study, we review the most recent works on the improvement of various techniques for development of radiolabeled magnetic and gold nanoprobes, and discuss the methods for targeted imaging and therapies. Results: The receptor-specific radiopharmaceuticals have been developed to localized radiotherapy in disease sites. Application of advanced multimodal imaging methods and related modality imaging agents labeled with various radioisotopes (e.g., 125I, 111In, 64Cu, 68Ga, 99mTc) and MNPs/GNPs have significant effects on treatment and prognosis of cancer therapy. In addition, the surface modification with biocompatible polymer such as polyethylene glycol (PEG) have resulted in development of stealth NPs that can evade the opsonization and immune clearance. These long-circulating agents can be decorated with homing agents as well as radioisotopes for targeted imaging and therapy purposes. Conclusion: The modified MNPs or GNPs have wide applications in concurrent diagnosis and therapy of various malignancies. Once armed with radioisotopes, these nanosystems (NSs) can be exploited for combined multimodality imaging with photothermal/photodynamic therapy while delivering the loaded drugs or genes to the targeted cells/tissues. These NSs will be a game changer in combating various cancers.

show abstract

“…Small size, controllable surface potential, superior colloidal stability and fine transverse relaxivity were the properties of this NS as a theranostic probe. 95 …”

Section: Radiolabeled Mnpsmentioning

confidence: 99%

Radiolabeled theranostics: magnetic and gold nanoparticles

et al. 2016

View full text Add to dashboard Cite

show abstract

“…[768] Since FDA approved iron oxide nanoparticles, they have been served the most popular MRI contrast components to further the utilization of PET/MRI multimodal imaging by influencing the T 2 relaxation time of nearby water protons as well as being biodegradable and nontoxic. [769] Furthermore, other metals such as manganese [770] and cobalt [771] have been added to iron oxide nanoparticles to increase their contrast-enhancing efficiency by gaining superior magnetic anisotropy, [772] as well reducing the particle size for longer blood circulation times. [773] Simultaneously, PET signals are in charge of resolving the lack of functional information provided by MR images.…”

Section: Positron Emission Tomographymentioning

confidence: 99%

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Mosayebi

Kiyasatfar

Laurent

2017

Adv Healthcare Materials

192

171

View full text Add to dashboard Cite

In order to translate nanotechnology into medical practice, magnetic nanoparticles (MNPs) have been presented as a class of non‐invasive nanomaterials for numerous biomedical applications. In particular, MNPs have opened a door for simultaneous diagnosis and brisk treatment of diseases in the form of theranostic agents. This review highlights the recent advances in preparation and utilization of MNPs from the synthesis and functionalization steps to the final design consideration in evading the body immune system for therapeutic and diagnostic applications with addressing the most recent examples of the literature in each section. This study provides a conceptual framework of a wide range of synthetic routes classified mainly as wet chemistry, state‐of‐the‐art microfluidic reactors, and biogenic routes, along with the most popular coating materials to stabilize resultant MNPs. Additionally, key aspects of prolonging the half‐life of MNPs via overcoming the sequential biological barriers are covered through unraveling the biophysical interactions at the bio–nano interface and giving a set of criteria to efficiently modulate MNPs' physicochemical properties. Furthermore, concepts of passive and active targeting for successful cell internalization, by respectively exploiting the unique properties of cancers and novel targeting ligands are described in detail. Finally, this study extensively covers the recent developments in magnetic drug targeting and hyperthermia as therapeutic applications of MNPs. In addition, multi‐modal imaging via fusion of magnetic resonance imaging, and also innovative magnetic particle imaging with other imaging techniques for early diagnosis of diseases are extensively provided.

show abstract

“…Another interesting chelator-free labeling method was reported by Cui and co-workers, who labeled 18 F to Fe 3 O 4 @Al(OH) 3 by taking advantages of the high affinity between Al(OH) 3 and fluoride anions. 48 …”

Section: Chelator-free Synthesis Of Radiolabeled Iron Oxide Nanopartimentioning

confidence: 99%

Engineering of radiolabeled iron oxide nanoparticles for dual‐modality imaging

Ferreira

Chen

et al. 2015

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Over the last decade, radiolabeled iron oxide nanoparticles have been developed as promising contrast agents for dual-modality positron emission tomography/magnetic resonance imaging (PET/MRI) or single-photon emission computed tomography/magnetic resonance imaging (SPECT/MRI). The combination of PET (or SPECT) with MRI can offer synergistic advantages for non-invasive, sensitive, high-resolution, and quantitative imaging, which is suitable for early detection of various diseases such as cancer. Here, we summarize the recent advances on radiolabeled iron oxide nanoparticles for dual-modality imaging, through the use of a variety of PET (and SPECT) isotopes by using both chelator-based and chelator-free radiolabeling techniques.

show abstract

Aluminium hydroxide stabilised MnFe2O4 and Fe3O4 nanoparticles as dual-modality contrasts agent for MRI and PET imaging

Cited by 78 publications

References 26 publications

Radiolabeled theranostics: magnetic and gold nanoparticles

Radiolabeled theranostics: magnetic and gold nanoparticles

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Engineering of radiolabeled iron oxide nanoparticles for dual‐modality imaging

Contact Info

Product

Resources

About